modelProcaineBenzylpenicillin

Diagram of ProcaineBenzylpenicillin

Extends from Pharmacolibrary.Drugs.ATC.J.J01CE09.

Information

name:ProcaineBenzylpenicillin
ATC code:J01CE09
route:intramuscular
compartments:1
dosage:1200000mg
volume of distribution:0.25L
clearance:0.7L/h
other parameters in model implementation

Procaine benzylpenicillin, also known as penicillin G procaine, is a combination of benzylpenicillin (penicillin G) and the local anesthetic procaine. It is an intramuscularly administered long-acting antibiotic used for various bacterial infections, such as syphilis, due to its prolonged release. Approved and widely used until recently in clinical settings, it is still used for select indications including syphilis and certain streptococcal infections.

Pharmacokinetics

Pharmacokinetic parameters estimated for healthy adult humans after intramuscular administration, as no recent primary articles with explicit compartment-model parameters were found.

References

  1. Tshefu, A, et al., & Cousens, S (2015). Oral amoxicillin compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with fast breathing when referral is not possible: a randomised, open-label, equivalence trial. Lancet (London, England) 385(9979) 1758–1766. DOI:10.1016/S0140-6736(14)62285-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25842223

  2. Baqui, AH, et al., & Black, RE (2015). Safety and efficacy of alternative antibiotic regimens compared with 7 day injectable procaine benzylpenicillin and gentamicin for outpatient treatment of neonates and young infants with clinical signs of severe infection when referral is not possible: a randomised, open-label, equivalence trial. The Lancet. Global health 3(5) e279–e287. DOI:10.1016/S2214-109X(14)70347-X PUBMED:https://pubmed.ncbi.nlm.nih.gov/25841891

  3. Tshefu, A, et al., & Cousens, S (2015). Simplified antibiotic regimens compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised, open-label, equivalence trial. Lancet (London, England) 385(9979) 1767–1776. DOI:10.1016/S0140-6736(14)62284-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25842221

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)